# HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES: Anti-CD38 isatuximab Immunotherapy in Hidradenitis Suppurativa: a randomized, double-blinded, placebo-controlled, seamless phase 2a/2b trial

**Lab Budget Score:** 70/100

| Field | Value |
|---|---|
| Organization | HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES |
| Location | EAST LANSING, MI |
| Project | Anti-CD38 isatuximab Immunotherapy in Hidradenitis Suppurativa: a randomized, double-blinded, placebo-controlled, seamless phase 2a/2b trial |
| Project number | 4UH3AR085895-02 |
| Mechanism | UH3 |
| Institute | National Institute of Arthritis and Musculoskeletal and Skin Diseases |
| Award | $2,071,075 |
| Awarded | 2026-09-09 |
| Project period | 2025-08-01 to 2031-08-31 |
| UEI | NH77YPDEGG84 |

## Why this score
- Award of $1M or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11526578). Last refreshed: 2026-11-04T21:37:56.465Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.